<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-31621" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Hyperbaric Treatment of Ischemia Reperfusion Injury</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Robins</surname>
            <given-names>Marc</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Falkson</surname>
            <given-names>Samuel R.</given-names>
          </name>
          <aff>Massachusetts General Hospital, Department of Anesthesia, Critical Care and Pain Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Goldfarb</surname>
            <given-names>Jeremy</given-names>
          </name>
          <aff>Massachusetts Eye and Ear Infirmary</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Wyatt</surname>
            <given-names>H Alan</given-names>
          </name>
          <aff>LSUHSC-NO, West Jefferson Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Marc Robins declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Samuel Falkson declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jeremy Goldfarb declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>H Alan Wyatt declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>12</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-31621.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Ischemia-reperfusion injury can occur with any injury that involves the interruption of vascular flow. Potential causes include soft tissue crush injuries, myocardial ischemia, and stroke. Hyperbaric oxygen treatment is not only an adjunctive treatment aimed at reducing ischemic tissue damage but, when used early enough post-injury, may mitigate the ischemia-reperfusion response by modulating inflammation, supporting microcirculatory function, maintaining metabolic function in affected tissues, and decreasing the production of reactive oxygen species and oxidative tissue damage.</p>
        <p>Due to a paucity of available hyperbaric chambers in many regions and a lack of experience or knowledge regarding its indications, hyperbaric oxygen therapy is an often missed therapeutic option. This topic discusses the etiology and pathophysiology of ischemia-reperfusion injuries, reviews the treatment of these injuries with hyperbaric oxygen, and highlights the interprofessional team's role in managing patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify patients at risk of or presenting with ischemia-reperfusion injury.</p></list-item><list-item><p>Implement hyperbaric oxygen therapy as an adjunctive treatment for ischemia-reperfusion injury, following established guidelines and protocols.</p></list-item><list-item><p>Review the potential adverse effects of treating ischemia-reperfusion injury with hyperbaric oxygen.</p></list-item><list-item><p>Collaborate with an interprofessional healthcare team to manage patients with ischemia-reperfusion injuries, including coordinating the timing and duration of hyperbaric oxygen therapy and other treatment modalities.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=31621&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=31621">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-31621.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Ischemia-reperfusion injury (IRI) is a well-recognized phenomenon potentially occurring following nearly any ischemic insult to tissue. Upon restoring blood flow, a secondary reperfusion injury can further damage tissue.<xref ref-type="bibr" rid="article-31621.r1">[1]</xref><xref ref-type="bibr" rid="article-31621.r2">[2]</xref>&#x000a0;If initiated early, hyperbaric oxygen therapy (HBOT) can help ameliorate the damaging effects of reperfusion by modulating inflammation, supporting microcirculation, maintaining metabolic function in affected tissues, and decreasing the production of reactive oxygen species and oxidative tissue damage.<xref ref-type="bibr" rid="article-31621.r1">[1]</xref><xref ref-type="bibr" rid="article-31621.r3">[3]</xref>&#x000a0;Hyperbaric oxygen therapy involves the administration of 100% oxygen at an atmospheric pressure greater than 1 atmosphere absolute and elevates the partial pressure of oxygen in the blood and tissues. One atmosphere absolute (ATA) is the average atmospheric pressure exerted at sea level. The resulting 20-fold increase in dissolved oxygen in the blood reaches all body tissues, providing excess oxygen to tissues suffering from a lack of delivered oxygen.&#x000a0;</p>
        <p>Often, the secondary reperfusion injury is more severe than the initial insult. Injuries leading to possible IRI are:</p>
        <list list-type="bullet">
          <list-item>
            <p>direct traumatic tissue injuries;</p>
          </list-item>
          <list-item>
            <p>pressure-induced injuries;</p>
          </list-item>
          <list-item>
            <p>cold injuries or burns; and</p>
          </list-item>
          <list-item>
            <p>embolic, thrombotic, and inflammatory occlusive insults.<xref ref-type="bibr" rid="article-31621.r1">[1]</xref></p>
          </list-item>
        </list>
        <p>Clinical scenarios where IRI may manifest are:</p>
        <list list-type="bullet">
          <list-item>
            <p>following thrombolytic therapy for cerebrovascular accidents;</p>
          </list-item>
          <list-item>
            <p>massive trauma resuscitations;</p>
          </list-item>
          <list-item>
            <p>fasciotomy for compartment syndrome;</p>
          </list-item>
          <list-item>
            <p>restoration of blood flow to transplanted organs; and</p>
          </list-item>
          <list-item>
            <p>invasive cardiovascular interventions.<xref ref-type="bibr" rid="article-31621.r1">[1]</xref><xref ref-type="bibr" rid="article-31621.r4">[4]</xref>&#x000a0;</p>
          </list-item>
        </list>
        <p>The severity of the IRI that results following an ischemic event is a function of multiple factors, including the duration of ischemia, the size of the ischemic territory, and the metabolic function of the ischemic tissue.<xref ref-type="bibr" rid="article-31621.r1">[1]</xref>&#x000a0;The time at which irreversible tissue damage occurs varies based on the metabolic activity of the affected area, with sensitive tissues such as the brain showing evidence of irreversible damage after as little as 20 minutes.<xref ref-type="bibr" rid="article-31621.r5">[5]</xref><xref ref-type="bibr" rid="article-31621.r6">[6]</xref>&#x000a0;The subsequent IRI pattern of injury shares many common pathological features regardless of the tissue or organ involved. The common pathological features are:</p>
        <list list-type="bullet">
          <list-item>
            <p>oxidative stress;</p>
          </list-item>
          <list-item>
            <p>reactive oxygen species (ROS) production;</p>
          </list-item>
          <list-item>
            <p>inflammation;</p>
          </list-item>
          <list-item>
            <p>increased neutrophil-endothelial interaction with subsequent neutrophil infiltration of affected tissue;</p>
          </list-item>
          <list-item>
            <p>microvascular dysfunction; and</p>
          </list-item>
          <list-item>
            <p>tissue necrosis.<xref ref-type="bibr" rid="article-31621.r1">[1]</xref><xref ref-type="bibr" rid="article-31621.r7">[7]</xref>&#x000a0;</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-31621.s3" sec-type="Function">
        <title>Function</title>
        <p>Immediate reperfusion is often a necessary life-saving intervention for patients. Given that ischemia and hypoxic injury arise via insufficient oxygen delivery to tissue, one may think that restoration of adequate oxygen supply would remedy the problem. However, in IRI, reperfusion paradoxically leads to persistent and sometimes increasing tissue damage, as noted microscopically by preserved tissue architecture and relative cellularity in ischemic tissue, while tissue visualized following IRI reveals necrosis with neutrophil infiltration.<xref ref-type="bibr" rid="article-31621.r1">[1]</xref>&#x000a0;</p>
        <p>Tissue hypoxia causes mitochondrial dysfunction, oxidative damage, the activation of complement and inflammatory processes, and tissue death. Hyperbaric oxygen therapy aims to:</p>
        <list list-type="bullet">
          <list-item>
            <p>restore oxygen levels</p>
          </list-item>
          <list-item>
            <p>maintain cellular metabolism</p>
          </list-item>
          <list-item>
            <p>restore ATP production</p>
          </list-item>
          <list-item>
            <p>mitigate mitochondrial dysfunction</p>
          </list-item>
          <list-item>
            <p>prevent oxidative stress</p>
          </list-item>
          <list-item>
            <p>inhibit apoptosis</p>
          </list-item>
          <list-item>
            <p>trigger the production of secondary antioxidants</p>
          </list-item>
        </list>
        <p>All these effects aid in the recovery of damaged tissue, decrease cellular and tissue edema, stimulate growth factor production, and improve wound healing.&#x000a0;</p>
        <p><bold>Pathophysiology of Ischemia-Reperfusion Injury</bold>&#x000a0;</p>
        <p>The mechanism of injury associated with IRI involves the production of reactive oxygen species (ROS), microvascular vasoconstriction, and endothelial cell-neutrophil adhesion, causing neutrophil infiltration of the involved tissue.<xref ref-type="bibr" rid="article-31621.r1">[1]</xref><xref ref-type="bibr" rid="article-31621.r7">[7]</xref>&#x000a0;Reactive oxygen species are chemical entities with oxygen free radicals formed as a by-product of cellular metabolism involving oxygen. Reactive oxygen species likely play a significant role in IRI.<xref ref-type="bibr" rid="article-31621.r1">[1]</xref><xref ref-type="bibr" rid="article-31621.r8">[8]</xref>&#x000a0;Following tissue ischemia, reperfusion increases the production of xanthine oxidase, subsequently elevating the production of various ROS, including superoxide and hydrogen peroxide.<xref ref-type="bibr" rid="article-31621.r1">[1]</xref><xref ref-type="bibr" rid="article-31621.r9">[9]</xref>&#x000a0;The increased production of superoxide and hydrogen peroxide recruit neutrophils, which in turn, produce additional ROS.<xref ref-type="bibr" rid="article-31621.r1">[1]</xref><xref ref-type="bibr" rid="article-31621.r10">[10]</xref><xref ref-type="bibr" rid="article-31621.r11">[11]</xref>&#x000a0;Oxidative damage from the ROS causes tissue death.<xref ref-type="bibr" rid="article-31621.r1">[1]</xref><xref ref-type="bibr" rid="article-31621.r12">[12]</xref>&#x000a0;Normally, glutathione, an endogenous antioxidant, neutralizes ROS. However, the capacity of these neutralizing agents is overwhelmed in IRI.<xref ref-type="bibr" rid="article-31621.r1">[1]</xref><xref ref-type="bibr" rid="article-31621.r13">[13]</xref></p>
        <p>The recruited neutrophils cause inflammatory tissue damage, representing another critical factor in IRI pathophysiology. Driven by interactions with beta-2-integrins, many neutrophils bind to the vascular endothelium, causing the expression of endothelial cell adhesion molecules. These adhesion molecules augment neutrophils' invasion of local tissues and subsequent inflammatory cascades via secretion of ROS and tumor necrosis factor-&#x003b1;.<xref ref-type="bibr" rid="article-31621.r1">[1]</xref><xref ref-type="bibr" rid="article-31621.r2">[2]</xref><xref ref-type="bibr" rid="article-31621.r14">[14]</xref><xref ref-type="bibr" rid="article-31621.r15">[15]</xref><xref ref-type="bibr" rid="article-31621.r16">[16]</xref>&#x000a0;CD4+ lymphocyte levels are also elevated in the affected tissue and further contribute to the inflammatory milieu by stimulating local macrophage activity and increasing cytokine production.<xref ref-type="bibr" rid="article-31621.r2">[2]</xref><xref ref-type="bibr" rid="article-31621.r17">[17]</xref>&#x000a0;The net result of this inflammatory reaction serves to propagate IRI further.</p>
        <p>
<bold>Mechanisms of Action of Hyperbaric Oxygen Therapy</bold>
</p>
        <p>The primary mechanism of action of HBOT is hyperoxygenation and the restoration of oxygen to normal or above-normal levels in oxygen-deprived tissues. The secondary benefits of hyperoxygenation are vast and include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Vasoconstriction to reduce tissue edema and improve microcirculation</p>
          </list-item>
          <list-item>
            <p>Reduction of endothelial damage and restoration of cell-to-cell junctions</p>
          </list-item>
          <list-item>
            <p>Modulation of aquaporins that modulate water transport between cells and become dysfunctional during tissue ischemia</p>
          </list-item>
          <list-item>
            <p>Promotion of all active mechanisms that require ATP, like wound healing cascades, angiogenesis, and lymphogenesis</p>
          </list-item>
          <list-item>
            <p>Increased growth factor production</p>
          </list-item>
          <list-item>
            <p>Direct and indirect antimicrobial effects</p>
          </list-item>
          <list-item>
            <p>Mobilization of stem cells from bone marrow</p>
          </list-item>
          <list-item>
            <p>Enzymatic and non-enzymatic antioxidant protection</p>
          </list-item>
          <list-item>
            <p>Restoration of cellular ion homeostasis, reduction of acidosis, stabilization of cellular calcium, and restoration of mitochondrial oxidative phosphorylation</p>
          </list-item>
          <list-item>
            <p>Limiting the release of excitatory mediators, ROS toxicity, and apoptosis</p>
          </list-item>
          <list-item>
            <p>Increased levels of IL-10, an anti-inflammatory cytokine</p>
          </list-item>
          <list-item>
            <p>Limiting mitochondrial DNA damage</p>
          </list-item>
          <list-item>
            <p>Reducing the expression of adhesion molecules and endothelin-1</p>
          </list-item>
        </list>
        <p>Evidence from rat skin flap models suggests that HBOT partly increases skin flap survival by decreasing ROS's destructive effect in IRI.<xref ref-type="bibr" rid="article-31621.r1">[1]</xref><xref ref-type="bibr" rid="article-31621.r18">[18]</xref>&#x000a0;Hyperbaric oxygen therapy appears to produce this effect by modulating multiple pathways, including increasing both the function of free radical scavenging systems, such as superoxide dismutase, and antioxidant gene expression.<xref ref-type="bibr" rid="article-31621.r1">[1]</xref><xref ref-type="bibr" rid="article-31621.r18">[18]</xref><xref ref-type="bibr" rid="article-31621.r19">[19]</xref></p>
        <p>Hyperbaric oxygen therapy additionally helps decrease neutrophil-mediated inflammation that contributes to IRI. A key step for neutrophil infiltration into tissue during IRI involves neutrophil interaction with cell adhesion molecules and beta-2-integrins on the vascular endothelium. Rat and in vitro models demonstrate that HBOT helps limit the neutrophil-endothelial interaction in IRI, in part, by decreasing endothelial cell adhesion molecule expression.<xref ref-type="bibr" rid="article-31621.r1">[1]</xref><xref ref-type="bibr" rid="article-31621.r20">[20]</xref><xref ref-type="bibr" rid="article-31621.r21">[21]</xref>&#x000a0;Limiting neutrophil interaction with the endothelium may help decrease neutrophil presence in the affected tissue and the inflammatory component of the IRI.</p>
        <p>Hyperbaric oxygen therapy also appears to improve microcirculatory dysfunction that contributes to IRI. Rat models again show that HBOT, particularly when initiated during ischemia, helps decrease vasoconstriction associated with IRI.<xref ref-type="bibr" rid="article-31621.r1">[1]</xref><xref ref-type="bibr" rid="article-31621.r20">[20]</xref>&#x000a0;Many mechanisms likely contribute to this phenomenon, though in vitro research suggests stimulation of nitric oxide synthase by HBOT may increase nitric oxide levels and, thus, local vasodilation.<xref ref-type="bibr" rid="article-31621.r1">[1]</xref><xref ref-type="bibr" rid="article-31621.r21">[21]</xref>&#x000a0;Mitigating pathologic vasoconstriction during the IRI may help maintain nutrient delivery to tissues and help lessen tissue injury. In addition to acutely supporting microvascular function, rat models suggest HBOT may yield a longer-term benefit in the IRI setting by increasing vascular endothelial growth factor (VEGF) transcription and production, leading to angiogenesis and subsequently improved tissue perfusion.<xref ref-type="bibr" rid="article-31621.r1">[1]</xref><xref ref-type="bibr" rid="article-31621.r22">[22]</xref></p>
      </sec>
      <sec id="article-31621.s4" sec-type="Issues of Concern">
        <title>Issues of Concern</title>
        <p>As discussed, multiple mechanisms contribute to producing the pattern of IRI. Given the high prevalence of clinical scenarios where IRI may contribute to morbidity and mortality, such as myocardial infarctions and strokes, investigations into therapies to mitigate its severity, such as HBOT, are of importance.</p>
        <p>A limitation of HBOT for IRI is that for it to be effective, HBOT should begin within 6 hours of IRI. As of 2022, more than 1,000 hospitals in the United States offer hyperbaric oxygen therapy. Less than 100 offer 24-hour per day, 7-day-a-week availability for emergent and urgent programs. Only 60 can treat patients requiring critical care.&#x000a0;</p>
        <p>Hyperbaric oxygen therapy is a relatively safe treatment, with the most common side effect being middle ear barotrauma. Estimates suggest this occurs to varying degrees during approximately 10% of HBOT treatments. Middle ear barotrauma initially manifests as ear pain during decompression due to the patient experiencing difficulty equalizing the pressure in the middle ear with that of the external environment. However, its most severe form can result in tympanic membrane rupture.<xref ref-type="bibr" rid="article-31621.r23">[23]</xref>&#x000a0;For patients with persistent difficulty equalizing their ears, myringotomy may be helpful for those for whom HBOT would be highly beneficial. Tympanostomy tubes may be especially important in pediatric patients who cannot pressurize their ears. Another serious risk is central nervous system oxygen toxicity, which could lead to seizures. Minor risks include clouding of vision leading to cataract formation, sinus pressure, hypoglycemia, or claustrophobia.</p>
        <p>Contraindications for HBOT are untreated pneumothorax due to the risk of the pneumothorax worsening or acquiring tension physiology in the setting of increased barometric pressures.<xref ref-type="bibr" rid="article-31621.r24">[24]</xref>&#x000a0;Medications contraindicated with HBOT are:</p>
        <list list-type="bullet">
          <list-item>
            <p>Bleomycin due to interstitial pneumonitis. Patients should be off bleomycin for an extended period before treatment.</p>
          </list-item>
          <list-item>
            <p>Cisplatin due to impaired wound healing. Patients should be off cisplatin for an extended period before treatment.</p>
          </list-item>
          <list-item>
            <p>Disulfiram blocks superoxide dismutase. Discontinue disulfiram.</p>
          </list-item>
          <list-item>
            <p>Doxorubicin due to cardiotoxicity. Discontinue doxorubicin.</p>
          </list-item>
          <list-item>
            <p>Sulfamylon due to impaired wound healing. Discontinue sulfamylon.</p>
          </list-item>
        </list>
        <p>
<bold>Relative Contraindications</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Asthma</p>
          </list-item>
          <list-item>
            <p>Claustrophobia</p>
          </list-item>
          <list-item>
            <p>High fever</p>
          </list-item>
          <list-item>
            <p>Upper respiratory infection</p>
          </list-item>
          <list-item>
            <p>Hereditary spherocytosis&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Chronic obstructive pulmonary disease</p>
          </list-item>
          <list-item>
            <p>Pacemaker or implanted pain pump</p>
          </list-item>
          <list-item>
            <p>Pregnancy</p>
          </list-item>
          <list-item>
            <p>Seizures&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Eustachian tube dysfunction&#x000a0;</p>
          </list-item>
        </list>
        <p>A history of seizure disorder or a high fever may lower the patient's seizure threshold. Patients with implanted devices must ensure their device has been pressure tested. To date, the effects of HBOT in pregnancy are unknown. Hyperbaric oxygen therapy may be used in emergencies like carbon monoxide poisoning during pregnancy, as some studies show no adverse effects.&#x000a0;</p>
        <p>Additional therapies under investigation to help mitigate IRI include using agents that decrease the level of ROS and free radicals, such as superoxide dismutase and antibodies that block the neutrophil-endothelial interaction to limit neutrophil tissue invasion and inflammation.<xref ref-type="bibr" rid="article-31621.r1">[1]</xref><xref ref-type="bibr" rid="article-31621.r25">[25]</xref><xref ref-type="bibr" rid="article-31621.r26">[26]</xref>&#x000a0;Future research may investigate synergistic applications of multiple strategies, including HBOT, to find an optimal regimen for treating IRI.<bold>&#x000a0;</bold></p>
      </sec>
      <sec id="article-31621.s5" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Ischemia-reperfusion injury can occur following ischemia to many different tissues. Most nontraumatic ischemic events are related to vascular occlusion from atherosclerosis or other thromboembolic diseases. Given longer lifespans and an aging population, combined with high rates of metabolic disease, ischemic disease will likely increase in the future.<xref ref-type="bibr" rid="article-31621.r7">[7]</xref><xref ref-type="bibr" rid="article-31621.r27">[27]</xref>&#x000a0;Some risk factors like genetics, advanced age, and gender are irreversible. Lifestyle modification, diet, physical activity, maintaining a healthy weight, moderation of alcohol intake, and medications when appropriate will help mitigate additional risks.&#x000a0;</p>
        <p>Iatrogenic events like accidental extravasation of vasoactive substances, postoperative reactive inflammatory responses, or sudden hypotension in response to medical treatments can also cause IRI. Similarly, air-gas emboli can arise from insufflation during endoscopic procedures or delivery of anesthetic gases due to over-pressurization of poorly compliant lungs.&#x000a0;</p>
        <p>Essential questions regarding HBOT for IRI are:</p>
        <list list-type="bullet">
          <list-item>
            <p>When to initiate HBOT</p>
          </list-item>
          <list-item>
            <p>What treatment parameters to use, including treatment pressure and duration</p>
          </list-item>
          <list-item>
            <p>What number of HBOT treatments</p>
          </list-item>
        </list>
        <p>Hyperbaric oxygen therapy is generally administered between 1.9 and 3.0 ATA in specialized chambers that accommodate 1 to multiple people. Along with IRI, HBOT treats decompression sickness, carbon monoxide poisoning, diabetic wounds, delayed radiation injury, necrotizing fasciitis, gas gangrene, and refractory osteomyelitis. These decisions can be supported by considering factors such as the specific tissue affected, the time since the ischemia started, the etiology of the ischemia, the patient&#x02019;s overall clinical stability and status, and the patient&#x02019;s response to preceding HBOT sessions. Currently, the Undersea and Hyperbaric Medical Society (UHMS) does not have an approved indication specifically for IRI. However, several clinical conditions that are UHMS-approved indications for HBOT feature pathophysiology where IRI contributes to tissue damage and where reduction of IRI plays a role in the benefit of HBOT. Such UHMS-approved indications include compromised grafts or flaps, arterial insufficiency, acute traumatic ischemia such as crush injuries, and necrotizing soft tissue infections.<xref ref-type="bibr" rid="article-31621.r28">[28]</xref>&#x000a0;</p>
        <p>Assessing the UHMS recommendation surrounding the management of compromised grafts or flaps provides an understanding of the treatment paradigm involving how HBOT contributes to reducing IRI. In this condition, UHMS suggests treating compromised grafts or flaps at a pressure of 2 to 2.5 ATA for 90 to 120 minutes immediately upon recognition of tissue compromise. The healthcare team, which generally includes a hyperbaric physician and a plastic surgeon in this case, should continually evaluate the tissue&#x02019;s response to treatment to help determine how many hyperbaric treatments to pursue.</p>
        <p>Generally, a hyperbaric clinician should refer to the most up-to-date recommendations from the UHMS regarding optimal treatment paradigms that apply to the particular condition they are treating or to the guidelines at the individual clinician&#x02019;s specific practice location. Evidence suggests that HBOT is more effective when initiated earlier during the IRI, though specific treatment algorithms, such as those provided by UHMS, should be followed based on the specific clinical scenario.<xref ref-type="bibr" rid="article-31621.r1">[1]</xref><xref ref-type="bibr" rid="article-31621.r20">[20]</xref></p>
      </sec>
      <sec id="article-31621.s6" sec-type="Other Issues">
        <title>Other Issues</title>
        <p>
<bold>Pearls</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Ischemia-reperfusion injury can occur from any vascular interruption of blood flow, including trauma, thrombosis, embolism, and crush or pressure-related injuries.<xref ref-type="bibr" rid="article-31621.r1">[1]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Multiple factors, including a combination of ROS and oxidative damage, inflammation, and microvascular dysfunction, interact and contribute to IRI.<xref ref-type="bibr" rid="article-31621.r1">[1]</xref><xref ref-type="bibr" rid="article-31621.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p>Hyperbaric oxygen reduces IRI by limiting damage from ROS, improving microcirculatory function, suppressing excessive inflammation, and supporting angiogenesis.<xref ref-type="bibr" rid="article-31621.r1">[1]</xref><xref ref-type="bibr" rid="article-31621.r3">[3]</xref></p>
          </list-item>
          <list-item>
            <p>Seek guidance regarding treatment algorithms for specific ischemic conditions by consulting a qualified hyperbaric healthcare professional and the most up-to-date recommendations from the UHMS or the practice guidelines at an individual clinician&#x02019;s specific practice location.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-31621.s7" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Ischemia-reperfusion injury has the potential to occur in multiple clinical scenarios. Reperfusion after myocardial infarction, cerebrovascular accident, organ transplantation, and compartment syndrome are all common clinical scenarios encountered in modern medical practice. Reperfusion may result in tissue injury worse than the original ischemic insult. To improve patient care and reduce morbidity and mortality associated with IRI, healthcare professionals must understand the mechanisms underlying IRI and the benefits of HBOT. Clinicians across all specialties should know the clinical scenarios in which IRI occurs and the associated clinical findings. Hyperbaric oxygen treatment is not only an adjunctive treatment aimed at reducing ischemic tissue damage but, when used early enough post-injury, may help to mitigate the ischemia-reperfusion response.</p>
        <p>Patients affected by IRI often have healthcare professionals from multiple specialties involved in their care. The complexity necessitates a collaborative approach among clinicians to ensure patient-centered care and improve overall outcomes. Clinicians must contribute individual expertise while providing effective interprofessional communication to provide the best patient care and reduce morbidity and mortality. Initiation of HBOT will&#x000a0;reduce the amount of lost tissue while improving the patient's quality of life.</p>
      </sec>
      <sec id="article-31621.s8" sec-type="Nursing, Allied Health, and Interprofessional Team Interventions">
        <title>Nursing, Allied Health, and Interprofessional Team Interventions</title>
        <p>Clinicians and members of interprofessional teams need to be fully aware of the specific indications for hyperbaric oxygen therapy (HBOT) and the practical aspects of its administration. To enhance the process of administering HBOT, treatment teams can take specific steps before sending patients to an HBOT facility. Early communication with a hyperbaric team is critical to facilitate these steps. For instance, for patients with an endotracheal tube (ET) in place, filling the cuff of an ET tube with fluid instead of air may be necessary to prevent pressure-related complications in the HBOT chamber. An air-filled cuff can lose volume during chamber compression, leading to air leaks, improper endotracheal tube positioning, and compromised ventilation. Moreover, when patients require intravenous infusions and HBOT simultaneously, special pressure-rated tubing and pumps capable of withstanding the higher pressures of HBOT are necessary. Regular and early communication between the primary and hyperbaric teams can streamline care coordination, address the logistical aspects of hyperbaric treatment, and improve patient outcomes.</p>
      </sec>
      <sec id="article-31621.s9" sec-type="Nursing, Allied Health, and Interprofessional Team Monitoring">
        <title>Nursing, Allied Health, and Interprofessional Team Monitoring</title>
        <p>The interprofessional team overseeing hyperbaric therapy must actively monitor potential risks associated with the treatment. These risks include central nervous system and pulmonary oxygen toxicity, barotrauma to the inner ear, sinuses, and lungs, and confinement anxiety or claustrophobia.</p>
        <p>Vigilance regarding oxygen toxicity of the central nervous and pulmonary systems is essential, as the risk for these conditions increases with 100% oxygen pressurized above atmospheric pressure. Immediate symptom recognition is critical. The symptoms of central nervous system oxygen toxicity are:</p>
        <list list-type="bullet">
          <list-item>
            <p>Headache</p>
          </list-item>
          <list-item>
            <p>Tinnitus</p>
          </list-item>
          <list-item>
            <p>Visual changes</p>
          </list-item>
          <list-item>
            <p>Paresthesias</p>
          </list-item>
          <list-item>
            <p>Seizures</p>
          </list-item>
        </list>
        <p>Pulmonary oxygen toxicity symptoms are:</p>
        <list list-type="bullet">
          <list-item>
            <p>Tickle or burning sensation with inhalation</p>
          </list-item>
          <list-item>
            <p>Hemoptysis</p>
          </list-item>
          <list-item>
            <p>Dyspnea</p>
          </list-item>
        </list>
        <p>Early identification of these adverse effects by the interprofessional team facilitates timely interventions, improving patient outcomes.</p>
        <p>Additionally, the team should be aware of the heightened risk of fire associated with hyperbaric oxygen due to the high oxygen concentrations used. A fire within a hyperbaric chamber can be catastrophic. Removing flammable materials from chambers and prohibiting electronics help mitigate these risks and can help prevent accidents. Enforcing the hyperbaric team's policies on fire reduction strategies and promptly recognizing fires, if they occur, are ways the interprofessional team can contribute to reducing the risk of fire incidents.</p>
      </sec>
      <sec id="article-31621.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=31621&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=31621">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/31621/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=31621">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-31621.s11">
        <title>References</title>
        <ref id="article-31621.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Francis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Baynosa</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Ischaemia-reperfusion injury and hyperbaric oxygen pathways: a review of cellular mechanisms.</article-title>
            <source>Diving Hyperb Med</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>47</volume>
            <issue>2</issue>
            <fpage>110</fpage>
            <page-range>110-117</page-range>
            <pub-id pub-id-type="pmid">28641323</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31621.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Soares</surname>
                <given-names>ROS</given-names>
              </name>
              <name>
                <surname>Losada</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Jordani</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>&#x000c9;vora</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Castro-E-Silva</surname>
                <given-names>O</given-names>
              </name>
            </person-group>
            <article-title>Ischemia/Reperfusion Injury Revisited: An Overview of the Latest Pharmacological Strategies.</article-title>
            <source>Int J Mol Sci</source>
            <year>2019</year>
            <month>Oct</month>
            <day>11</day>
            <volume>20</volume>
            <issue>20</issue>
            <pub-id pub-id-type="pmid">31614478</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31621.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yilmaz</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tumkaya</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Effects of hyperbaric oxygen and iloprost on intestinal ischemia-reperfusion induced acute lung injury.</article-title>
            <source>Ann Surg Treat Res</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>96</volume>
            <issue>1</issue>
            <fpage>34</fpage>
            <page-range>34-40</page-range>
            <pub-id pub-id-type="pmid">30603632</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31621.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gordon</surname>
                <given-names>WT</given-names>
              </name>
              <name>
                <surname>Talbot</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Shero</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Osier</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>AE</given-names>
              </name>
              <name>
                <surname>Balsamo</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Stockinger</surname>
                <given-names>ZT</given-names>
              </name>
            </person-group>
            <article-title>Acute Extremity Compartment Syndrome and the Role of Fasciotomy in Extremity War Wounds.</article-title>
            <source>Mil Med</source>
            <year>2018</year>
            <month>Sep</month>
            <day>01</day>
            <volume>183</volume>
            <issue>suppl_2</issue>
            <fpage>108</fpage>
            <page-range>108-111</page-range>
            <pub-id pub-id-type="pmid">30189076</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31621.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kalogeris</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Baines</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Krenz</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Korthuis</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Ischemia/Reperfusion.</article-title>
            <source>Compr Physiol</source>
            <year>2016</year>
            <month>Dec</month>
            <day>06</day>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>113</fpage>
            <page-range>113-170</page-range>
            <pub-id pub-id-type="pmid">28135002</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31621.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ordy</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Wengenack</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Bialobok</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Coleman</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Rodier</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Baggs</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Dunlap</surname>
                <given-names>WP</given-names>
              </name>
              <name>
                <surname>Kates</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Selective vulnerability and early progression of hippocampal CA1 pyramidal cell degeneration and GFAP-positive astrocyte reactivity in the rat four-vessel occlusion model of transient global ischemia.</article-title>
            <source>Exp Neurol</source>
            <year>1993</year>
            <month>Jan</month>
            <volume>119</volume>
            <issue>1</issue>
            <fpage>128</fpage>
            <page-range>128-39</page-range>
            <pub-id pub-id-type="pmid">8432346</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31621.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hentia</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rizzato</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Camporesi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Muntean</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>S&#x00103;ndesc</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bosco</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>An overview of protective strategies against ischemia/reperfusion injury: The role of hyperbaric oxygen preconditioning.</article-title>
            <source>Brain Behav</source>
            <year>2018</year>
            <month>May</month>
            <volume>8</volume>
            <issue>5</issue>
            <fpage>e00959</fpage>
            <pub-id pub-id-type="pmid">29761012</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31621.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nakai</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tsuruta</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>What Are Reactive Oxygen Species, Free Radicals, and Oxidative Stress in Skin Diseases?</article-title>
            <source>Int J Mol Sci</source>
            <year>2021</year>
            <month>Oct</month>
            <day>06</day>
            <volume>22</volume>
            <issue>19</issue>
            <pub-id pub-id-type="pmid">34639139</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31621.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zweier</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Talukder</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>The role of oxidants and free radicals in reperfusion injury.</article-title>
            <source>Cardiovasc Res</source>
            <year>2006</year>
            <month>May</month>
            <day>01</day>
            <volume>70</volume>
            <issue>2</issue>
            <fpage>181</fpage>
            <page-range>181-90</page-range>
            <pub-id pub-id-type="pmid">16580655</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31621.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Inauen</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Granger</surname>
                <given-names>DN</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of cellular injury: potential sources of oxygen free radicals in ischemia/reperfusion.</article-title>
            <source>Microcirc Endothelium Lymphatics</source>
            <year>1989</year>
            <season>Jun-Oct</season>
            <volume>5</volume>
            <issue>3-5</issue>
            <fpage>143</fpage>
            <page-range>143-55</page-range>
            <pub-id pub-id-type="pmid">2700373</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31621.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pang</surname>
                <given-names>CY</given-names>
              </name>
            </person-group>
            <article-title>Ischemia-induced reperfusion injury in muscle flaps: pathogenesis and major source of free radicals.</article-title>
            <source>J Reconstr Microsurg</source>
            <year>1990</year>
            <month>Jan</month>
            <volume>6</volume>
            <issue>1</issue>
            <fpage>77</fpage>
            <page-range>77-83</page-range>
            <pub-id pub-id-type="pmid">2407843</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31621.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Steller</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms and genes of cellular suicide.</article-title>
            <source>Science</source>
            <year>1995</year>
            <month>Mar</month>
            <day>10</day>
            <volume>267</volume>
            <issue>5203</issue>
            <fpage>1445</fpage>
            <page-range>1445-9</page-range>
            <pub-id pub-id-type="pmid">7878463</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31621.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khalil</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Aziz</surname>
                <given-names>FA</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Reperfusion injury.</article-title>
            <source>Plast Reconstr Surg</source>
            <year>2006</year>
            <month>Mar</month>
            <volume>117</volume>
            <issue>3</issue>
            <fpage>1024</fpage>
            <page-range>1024-33</page-range>
            <pub-id pub-id-type="pmid">16525303</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31621.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wu</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Niu</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Tian</surname>
                <given-names>YF</given-names>
              </name>
            </person-group>
            <article-title>Heat Shock Protein 70 (HSP70) Reduces Hepatic Inflammatory and Oxidative Damage in a Rat Model of Liver Ischemia/Reperfusion Injury with Hyperbaric Oxygen Preconditioning.</article-title>
            <source>Med Sci Monit</source>
            <year>2018</year>
            <month>Nov</month>
            <day>12</day>
            <volume>24</volume>
            <fpage>8096</fpage>
            <page-range>8096-8104</page-range>
            <pub-id pub-id-type="pmid">30417859</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31621.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Seekamp</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ward</surname>
                <given-names>PA</given-names>
              </name>
            </person-group>
            <article-title>Ischemia-reperfusion injury.</article-title>
            <source>Agents Actions Suppl</source>
            <year>1993</year>
            <volume>41</volume>
            <fpage>137</fpage>
            <page-range>137-52</page-range>
            <pub-id pub-id-type="pmid">8317338</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31621.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yago</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Petrich</surname>
                <given-names>BG</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Shao</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ginsberg</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>McEver</surname>
                <given-names>RP</given-names>
              </name>
            </person-group>
            <article-title>Blocking neutrophil integrin activation prevents ischemia-reperfusion injury.</article-title>
            <source>J Exp Med</source>
            <year>2015</year>
            <month>Jul</month>
            <day>27</day>
            <volume>212</volume>
            <issue>8</issue>
            <fpage>1267</fpage>
            <page-range>1267-81</page-range>
            <pub-id pub-id-type="pmid">26169939</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31621.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nastos</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kalimeris</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Papoutsidakis</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tasoulis</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Lykoudis</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Theodoraki</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nastou</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Smyrniotis</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Arkadopoulos</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Global consequences of liver ischemia/reperfusion injury.</article-title>
            <source>Oxid Med Cell Longev</source>
            <year>2014</year>
            <volume>2014</volume>
            <fpage>906965</fpage>
            <pub-id pub-id-type="pmid">24799983</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31621.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaelin</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Im</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Myers</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Manson</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>Hoopes</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>The effects of hyperbaric oxygen on free flaps in rats.</article-title>
            <source>Arch Surg</source>
            <year>1990</year>
            <month>May</month>
            <volume>125</volume>
            <issue>5</issue>
            <fpage>607</fpage>
            <page-range>607-9</page-range>
            <pub-id pub-id-type="pmid">2331219</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31621.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Godman</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Joshi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Giardina</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Perdrizet</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hightower</surname>
                <given-names>LE</given-names>
              </name>
            </person-group>
            <article-title>Hyperbaric oxygen treatment induces antioxidant gene expression.</article-title>
            <source>Ann N Y Acad Sci</source>
            <year>2010</year>
            <month>Jun</month>
            <volume>1197</volume>
            <fpage>178</fpage>
            <page-range>178-83</page-range>
            <pub-id pub-id-type="pmid">20536847</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31621.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zamboni</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Roth</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Russell</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Graham</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Suchy</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kucan</surname>
                <given-names>JO</given-names>
              </name>
            </person-group>
            <article-title>Morphologic analysis of the microcirculation during reperfusion of ischemic skeletal muscle and the effect of hyperbaric oxygen.</article-title>
            <source>Plast Reconstr Surg</source>
            <year>1993</year>
            <month>May</month>
            <volume>91</volume>
            <issue>6</issue>
            <fpage>1110</fpage>
            <page-range>1110-23</page-range>
            <pub-id pub-id-type="pmid">8479978</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31621.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Buras</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Stahl</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>Svoboda</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Reenstra</surname>
                <given-names>WR</given-names>
              </name>
            </person-group>
            <article-title>Hyperbaric oxygen downregulates ICAM-1 expression induced by hypoxia and hypoglycemia: the role of NOS.</article-title>
            <source>Am J Physiol Cell Physiol</source>
            <year>2000</year>
            <month>Feb</month>
            <volume>278</volume>
            <issue>2</issue>
            <fpage>C292</fpage>
            <page-range>C292-302</page-range>
            <pub-id pub-id-type="pmid">10666024</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31621.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sheikh</surname>
                <given-names>AY</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Rollins</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Hopf</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Hussain</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Hunt</surname>
                <given-names>TK</given-names>
              </name>
            </person-group>
            <article-title>Effect of hyperoxia on vascular endothelial growth factor levels in a wound model.</article-title>
            <source>Arch Surg</source>
            <year>2000</year>
            <month>Nov</month>
            <volume>135</volume>
            <issue>11</issue>
            <fpage>1293</fpage>
            <page-range>1293-7</page-range>
            <pub-id pub-id-type="pmid">11074883</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31621.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nasole</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Zanon</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Marcolin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Bosco</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Middle ear barotrauma during hyperbaric oxygen therapy; a review of occurrences in 5,962 patients.</article-title>
            <source>Undersea Hyperb Med</source>
            <string-date>2019 Mar-Apr-May</string-date>
            <volume>46</volume>
            <issue>2</issue>
            <fpage>101</fpage>
            <page-range>101-106</page-range>
            <pub-id pub-id-type="pmid">31051054</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31621.r24">
          <label>24</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Gawdi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <chapter-title>Hyperbaric Contraindications</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>4</month>
            <day>8</day>
            <pub-id pub-id-type="pmid">32491593</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31621.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Feller</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Roth</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Russell</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Eagleton</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Suchy</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Debs</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Experimental evaluation of oxygen free radical scavengers in the prevention of reperfusion injury to skeletal muscle.</article-title>
            <source>Ann Plast Surg</source>
            <year>1989</year>
            <month>Apr</month>
            <volume>22</volume>
            <issue>4</issue>
            <fpage>321</fpage>
            <page-range>321-31</page-range>
            <pub-id pub-id-type="pmid">2539767</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31621.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mori</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>del Zoppo</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Chambers</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Copeland</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Arfors</surname>
                <given-names>KE</given-names>
              </name>
            </person-group>
            <article-title>Inhibition of polymorphonuclear leukocyte adherence suppresses no-reflow after focal cerebral ischemia in baboons.</article-title>
            <source>Stroke</source>
            <year>1992</year>
            <month>May</month>
            <volume>23</volume>
            <issue>5</issue>
            <fpage>712</fpage>
            <page-range>712-8</page-range>
            <pub-id pub-id-type="pmid">1579969</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31621.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Go</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Mozaffarian</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Roger</surname>
                <given-names>VL</given-names>
              </name>
              <name>
                <surname>Benjamin</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Berry</surname>
                <given-names>JD</given-names>
              </name>
              <name>
                <surname>Blaha</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Dai</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ford</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Fox</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Franco</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Fullerton</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Gillespie</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hailpern</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Heit</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Howard</surname>
                <given-names>VJ</given-names>
              </name>
              <name>
                <surname>Huffman</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Judd</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Kissela</surname>
                <given-names>BM</given-names>
              </name>
              <name>
                <surname>Kittner</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Lackland</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Lichtman</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Lisabeth</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Mackey</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Magid</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Marcus</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Marelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Matchar</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>McGuire</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Mohler</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Moy</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Mussolino</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Neumar</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Nichol</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pandey</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Paynter</surname>
                <given-names>NP</given-names>
              </name>
              <name>
                <surname>Reeves</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Sorlie</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Stein</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Towfighi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Turan</surname>
                <given-names>TN</given-names>
              </name>
              <name>
                <surname>Virani</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Woo</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Turner</surname>
                <given-names>MB</given-names>
              </name>
              <collab>American Heart Association Statistics Committee and Stroke Statistics Subcommittee</collab>
            </person-group>
            <article-title>Heart disease and stroke statistics--2014 update: a report from the American Heart Association.</article-title>
            <source>Circulation</source>
            <year>2014</year>
            <month>Jan</month>
            <day>21</day>
            <volume>129</volume>
            <issue>3</issue>
            <fpage>e28</fpage>
            <page-range>e28-e292</page-range>
            <pub-id pub-id-type="pmid">24352519</pub-id>
          </element-citation>
        </ref>
        <ref id="article-31621.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ortega</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Fraile-Martinez</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a-Montero</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Callej&#x000f3;n-Pel&#x000e1;ez</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>S&#x000e1;ez</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>&#x000c1;lvarez-Mon</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Garc&#x000ed;a-Honduvilla</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Monserrat</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>&#x000c1;lvarez-Mon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bujan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Canals</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>A General Overview on the Hyperbaric Oxygen Therapy: Applications, Mechanisms and Translational Opportunities.</article-title>
            <source>Medicina (Kaunas)</source>
            <year>2021</year>
            <month>Aug</month>
            <day>24</day>
            <volume>57</volume>
            <issue>9</issue>
            <pub-id pub-id-type="pmid">34577787</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
